Author: sri_mamah

Research data sharing: the EDCTP Knowledge Hub

Today, a first public version of a knowledge tool for research data sharing was presented at the EDCTP Forum. It was developed by a team from The Global Health Network. The session aimed to introduce the tool to an audience of clinical researchers and to receive as much feedback from them as possible.

Dr Michael Makanga, EDCTP Executive Director, introduced this EDCTP-funded project. Open data sharing, in general, is seen more and more as a key factor for progress in many areas. From banking to climate change, data and know-how are shared in professional fields to make faster progress by learning best practices and housing better data.

Opening session of the Ninth EDCTP Forum

The welcoming session at a large conference is important in setting the pace for the remainder of the event. The Ninth Forum got off to a fine start on Monday evening, as it contained not only welcome messages from our Portuguese hosts, important updates on the progress of EDCTP and some inspiring keynote addresses, but also music and prizes!

Michael Makanga welcomed delegates and thanked both our hosts and the sponsoring organisations, before giving an outline of the scope of the presentations, discussions, workshops and plenary sessions that will be taking place. He announced that EDCTP´s fora will continue to be held every two years, but will in future alternate between African and European venues.

Prof. Clara Menéndez

ISGlobal, Project Coordinator

Chair of Executive Committee

Medicines for Malaria

Antonella Bacchieri

Biostatistician

Dr Montserrat Blazquez

EDCTP, Programme Officer

Observer

Dr Hanu Ramachandruni

MMV, Senior Director, Technical Product Development, Research & Development

Dr Myriam El Gaaloul

MMV, Associate Director, Clinical Sciences
Research & Development

Dr André-Marie Tchouatieu

MMV, Associate Director Access and Product Management

Dr George Jagoe

MMV, Executive vice president

Dr Stephan Chalon

MMV, VP Experimental Medicine & Clinical Pharmacology

Research & Development

Dr Stehpan Duparc

MMV, Chief Medical Officer
Research & Development

9th EDCTP Forum, Lisbon 17-21, September

Clinical research and sustainable development in sub-Saharan Africa: the impact of North-South partnerships
The EDCTP Forum is a biennial event that provides an international platform for the presentation and discussion of frontier research to address the burden of poverty-related infectious diseases in sub-Saharan Africa, and also capacity development and networking activities to support these goals.

The EDCTP Forum attracts a diverse audience, including representatives from research institutions and universities, the larger scientific community, health care providers, governments, regional bodies, regulators, civil society and public and private research and development partners.

12

12. Gonzalez R, Mombo-Ngoma G, Ouedraogo S, et al. Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial. PLoS Med. 2014; 11:e1001733.

Projects Malaria in Pregnancy Preventive Alternative Drugs (MiPPAD)

This project is aimed to develop new anti-malarial drugs in pregnancy prevention, promote European and African research collaboration and strengthen the research capacity of African institutions
Malaria in Pregnancy (MiP) is one of the most important preventable causes of low birth weight deliveries worldwide and a major cause of severe maternal anaemia contributing to maternal mortality. To find effective preventive interventions to reduce the incidence and consequences of malaria infection in pregnant women is a priority in endemic countries. As part of the planned activities of the Malaria in Pregnancy consortium, a global initiative bringing together a research consortium of 40 partner institutions in 28 countries around the world, this project aims not only to develop new anti-malaria in pregnancy prevention but also to promote European and to African research collaboration and to strengthen the capacity of African institutions to conduct clinical research..”

28

28. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. The New England journal of medicine. 2016; 374:1647-60.

27

27. Castillo P, Ussene E, Ismail MR, et al. Pathological Methods Applied to the Investigation of Causes of Death in Developing Countries: Minimally Invasive Autopsy Approach. PloS one. 2015; 10:e0132057.

29

29. Kayentao K, Doumbo OK, Penali LK, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malaria journal. 2012; 11:364.

26

26. Sigauque B, Vubil D, Sozinho A, et al. Haemophilus influenzae type b disease among children in rural Mozambique: impact of vaccine introduction. The Journal of pediatrics. 2013; 163:S19-24.

25

25. Naniche D, Bardaji A, Lahuerta M, et al. Impact of maternal human immunodeficiency virus infection on birth outcomes and infant survival in rural Mozambique. Am J Trop Med Hyg. 2009; 80:870-6.

30

30. Mombo-Ngoma G, Supan C, Dal-Bianco MP, et al. Phase I randomized dose-ascending placebo-controlled trials of ferroquine–a candidate anti-malarial drug–in adults with asymptomatic Plasmodium falciparum infection. Malaria journal. 2011; 10:53.

31

31. Ramharter M, Kurth F, Schreier AC, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. The Journal of infectious diseases. 2008; 198:911- 9.

32

32. Desai M, Gutman J, L’Lanziva A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine- pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015; 386:2507-19.

24

24. Gonzalez R, Augusto OJ, Munguambe K, et al. HIV Incidence and Spatial Clustering in a Rural Area of Southern Mozambique. PloS one. 2015; 10:e0132053.

33

33. Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. N Engl J Med. 2016; 374:928-39.

23

23. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet (London, England). 2009; 374:1533-42..

36

36. Pekyi D, Ampromfi AA, Tinto H, et al. Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. N Engl J Med. 2016; 374:913-27.

10

10. Zou G. A modified poisson regression approach to prospective studies with binary data. American journal of epidemiology. 2004; 159:702-6.

9

9. WHO. Consolidated Guidelines on The Use of Antiretroviral Drugs for Treating And Preventing HIV infection. WHO. 2013.

14

14. Bouyou-Akotet MK, Mawili-Mboumba DP and Kombila M. Antenatal care visit attendance, intermittent preventive treatment and bed net use during pregnancy in Gabon. BMC pregnancy and childbirth. 2013; 13:52.

15

15. Mombo-Ngoma G, Mackanga JR, Gonzalez R, et al. Young adolescent girls are at high risk for adverse pregnancy outcomes in sub-Saharan Africa: an observational multicountry study. BMJ open. 2016; 6:e011783.

16

16. Gonzalez R, Munguambe K, Aponte J, et al. High HIV prevalence in a southern semi-rural area of Mozambique: a community-based survey. HIV Med. 2012.

17

17. Manego RZ, Mombo-Ngoma G, Witte M, et al. Demography, maternal health and the epidemiology of malaria and other major infectious diseases in the rural department Tsamba-Magotsi, Ngounie Province, in central African Gabon. BMC Public Health. 2017; 17:130.

18

18. Caron M, Lekana-Douki SE, Makuwa M, et al. Prevalence, genetic diversity and antiretroviral drugs resistance-associated mutations among untreated HIV-1-infected pregnant women in Gabon, central Africa. BMC infectious diseases. 2012; 12:64.

19

19. Lahuerta M, Aparicio E, Bardaji A, et al. Rapid spread and genetic diversification of HIV type 1 subtype C in a rural area of southern Mozambique. AIDS research and human retroviruses. 2008; 24:327-35.

20

UNAIDS. Mozambique country Fact sheet. 2016:

21

21. Ministère-de-la-Santé-et-de-la-Prévoyance-sociale-Gabon. Rapport National sur la Réponse au VIH/SIDA 2014. 2015

22

22. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004; 364:1411-20.

34

34. Rijken MJ, McGready R, Boel ME, et al. Dihydroartemisinin-piperaquine rescue treatment of multidrug- resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Am J Trop Med Hyg. 2008; 78:543-5.

35

35. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PloS one. 2014; 9:e84976.

13

13. Menendez C, Bardaji A, Sigauque B, et al. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PloS one. 2008; 3:e1934.

11

11. Zou GY and Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. Statistical methods in medical research. 2013; 22:661-70.

37

37. Desai M, Gutman J, L’Lanziva A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine- pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015.